Login to Your Account

Other News To Note

Friday, March 9, 2012
• Lipid Therapeutics GmbH, of Heidelberg, Germany, said it inked a licensing deal granting Dr. Falk Pharma GmbH, of Freiburg, Germany, rights to lead product LT-02 for ulcerative colitis. Specific terms were not disclosed, but Lipid will receive an up-front fee and be entitled to potential milestones and royalty payments.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription